Validation of an Anti-Protective Antigen ELISA for Quantitative IgG Evaluation in B. anthracis Immunized Horses

  title={Validation of an Anti-Protective Antigen ELISA for Quantitative IgG Evaluation in B. anthracis Immunized Horses},
  author={Marc Caldwell and Terri Hathcock and Br Kv},
The potency test for anthrax vaccines has historically involved the challenge of actively or passively immunized laboratory animals with a fully virulent strain of Bacillus anthracis. Lethal challenge studies with the archetypal virulent strains such as B. anthracis Ames strain present considerable difficulties in laboratory management and handling and are too inefficient for the early evaluation of alternative preventative and therapeutic interventions. An ELISA for the evaluation of antibody… 

Figures and Tables from this paper

Development of Enzyme Linked Immunosorbent Assay for humoral immuneresponse and infection monitoring of anthrax

The Anti- PA4 ELISA was developed and the validation studies to evaluate the response of the antibody to the Anthrax vaccine and distinction between disease and vaccination in mice are conducted.



Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice.

Search for Correlates of Protective Immunity Conferred by Anthrax Vaccine

Results clearly demonstrate that neutralizing antibodies to PA constitute a major component of the protective immunity against anthrax and suggest that this parameter could be used as a surrogate marker for protection.

Contribution of Immunological Memory to Protective Immunity Conferred by a Bacillus anthracis Protective Antigen-Based Vaccine

The practical implications from the studies reported herein are that the protective capacity of memory depends on the PA dose used for the primary immunization and that the effectiveness of booster immunizations for the postexposure treatment of anthrax may be very limited when no detectable antibodies are present in primed animals prior to Bacillus anthracis spore exposure.

Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig

It is concluded that antibodies to toxin components may not be sufficient to provide protection against all strains of B. anthracis and that other antigens may play a role in active immunity and that the efficacy of anthrax vaccines must be tested by using vaccine-resistant isolates ifprotection against all possible challenge strains is to be assured.

Anthrax Spores Make an Essential Contribution to Vaccine Efficacy

It is demonstrated that the addition of formaldehyde-inactivated spores of B. anthracis to PA elicits total protection against challenge with virulent B.Anthrax strains in mice and guinea pigs, suggesting that spore antigens contribute to protection.